Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer

(2019) Lukas W. Pfannenstiel et al.   Cancer Immunology Research

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

(2019) Kurt A. Schalper et al.   NATURE MEDICINE

CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling

(2019) Angela Yan et al.   JOURNAL OF NEUROSCIENCE

Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39

(2019) Maisa C. Takenaka et al.   NATURE NEUROSCIENCE

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach

(2019) J. H. Azambuja et al.   MOLECULAR NEUROBIOLOGY

Recovering Gene Interactions from Single-Cell Data Using Data Diffusion

(2018) David van Dijk et al.   CELL

Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

(2018) Elham Azizi et al.   CELL

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth

(2018) J. H. Azambuja et al.   MOLECULAR NEUROBIOLOGY

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses

(2017) Valerie Chew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

(2017) Michael A. Cannarile et al.   Journal for ImmunoTherapy of Cancer

CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells

(2016) Alan L. Chang et al.   CANCER RESEARCH

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

(2016) Takuro Saito et al.   NATURE MEDICINE

Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis

(2016) Ying Wang et al.   ONCOLOGY REPORTS

Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis

(2015) Jacob H. Levine et al.   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data

(2015) Sofie Van Gassen et al.   CYTOMETRY PART A

Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm

(2015) Eli R Zunder et al.   Nature Protocols

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints

(2015) Jun Wei et al.   NEURO-ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis

(2014) Edward C. Stack et al.   METHODS

Normalization of mass cytometry data with bead standards

(2013) Rachel Finck et al.   CYTOMETRY PART A

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

(2013) El-ad David Amir et al.   NATURE BIOTECHNOLOGY

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

CD39 and CD73 in immunity and inflammation

(2013) Luca Antonioli et al.   TRENDS IN MOLECULAR MEDICINE

CCL5, CCR1 and CCR5 in murine glioblastoma: Immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5

(2012) Kien Pham et al.   JOURNAL OF NEUROIMMUNOLOGY

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE